ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Up 5.3% in August

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 9,500,000 shares, a growth of 5.3% from the August 15th total of 9,020,000 shares. Based on an average daily trading volume, of 3,700,000 shares, the short-interest ratio is presently 2.6 days.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ADMA. HC Wainwright boosted their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Mizuho boosted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, Cantor Fitzgerald lifted their target price on ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $18.71 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. The firm has a market capitalization of $4.34 billion, a P/E ratio of -935.50 and a beta of 0.61. ADMA Biologics has a 1-year low of $3.06 and a 1-year high of $19.34. The company’s 50-day moving average is $15.33 and its 200 day moving average is $10.71.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. During the same period in the prior year, the business posted ($0.02) earnings per share. The company’s revenue for the quarter was up 78.4% on a year-over-year basis. Research analysts forecast that ADMA Biologics will post 0.49 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 466,900 shares of company stock worth $8,224,121. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently added to or reduced their stakes in the stock. LSV Asset Management bought a new stake in shares of ADMA Biologics during the first quarter valued at approximately $1,028,000. BNP Paribas Financial Markets increased its holdings in ADMA Biologics by 152.2% during the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after buying an additional 442,315 shares during the period. Alberta Investment Management Corp raised its position in shares of ADMA Biologics by 32.4% in the 4th quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock worth $2,083,000 after acquiring an additional 112,831 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of ADMA Biologics by 90.7% during the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock worth $7,717,000 after purchasing an additional 556,175 shares during the last quarter. Finally, Inspire Investing LLC boosted its position in ADMA Biologics by 125.2% during the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock valued at $1,249,000 after purchasing an additional 105,256 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.